189 related articles for article (PubMed ID: 3115027)
21. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
[TBL] [Abstract][Full Text] [Related]
22. Vacuum curettage by the Vabrar method. A simple procedure for endometrial diagnosis.
Einerth Y
Acta Obstet Gynecol Scand; 1982; 61(4):373-6. PubMed ID: 7148413
[TBL] [Abstract][Full Text] [Related]
23. The management of endometrial hyperplasia: an evaluation of current practice.
Clark TJ; Neelakantan D; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):259-64. PubMed ID: 16246481
[TBL] [Abstract][Full Text] [Related]
24. Hysteroscopic evaluation of intrauterine progesterone contraceptive system as a treatment for abnormal uterine bleeding.
Scarselli G; Mencaglia L; Tantini C; Colafranceschi M; Taddei G
Acta Eur Fertil; 1984; 15(4):279-82. PubMed ID: 6240880
[TBL] [Abstract][Full Text] [Related]
25. Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study.
Scarselli G; Bargelli G; Taddei GL; Marchionni M; Peruzzi E; Pieralli A; Mattei A; Buccoliero AM; Fambrini M
Fertil Steril; 2011 Jan; 95(1):420-2. PubMed ID: 20723889
[TBL] [Abstract][Full Text] [Related]
26. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
27. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
Haoula ZJ; Walker KF; Powell MC
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
[TBL] [Abstract][Full Text] [Related]
28. [Contraception in the hypertensive woman using a vaginal ring delivering estradiol and norgestrel].
Elkik F; Basdevant A; Corvol P
Arch Mal Coeur Vaiss; 1985 Oct; 78(11):1737-9. PubMed ID: 3938250
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a levonorgestrel-releasing intrauterine system for treating endometrial hyperplasia in patients with polycystic ovary syndrome.
Lin M; Xu X; Wang Y; Hu Y; Zhao Y
Gynecol Obstet Invest; 2014; 78(1):41-4. PubMed ID: 24852134
[TBL] [Abstract][Full Text] [Related]
30. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
[TBL] [Abstract][Full Text] [Related]
31. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia.
Edris F; Vilos GA; Al-Mubarak A; Ettler HC; Hollett-Caines J; Abu-Rafea B
J Minim Invasive Gynecol; 2007; 14(1):68-73. PubMed ID: 17218233
[TBL] [Abstract][Full Text] [Related]
32. Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy.
Rizkalla HF; Higgins M; Kelehan P; O'Herlihy C
Int J Gynecol Pathol; 2008 Jan; 27(1):74-8. PubMed ID: 18156979
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
34. The effect of intrauterine progesterone on the DNA-content in isolated human endometrial cells.
Johannisson E; Langren BM; Hagenfeldt K
Acta Cytol; 1977; 21(3):441-6. PubMed ID: 268127
[TBL] [Abstract][Full Text] [Related]
35. Comparison of diagnostic accuracy between endometrial curettage and pipelle aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group Study (KGOG 2019).
Kim MK; Seong SJ; Lee TS; Ki KD; Lim MC; Kim YH; Kim K; Joo WD
Jpn J Clin Oncol; 2015 Oct; 45(10):980-2. PubMed ID: 26206899
[TBL] [Abstract][Full Text] [Related]
36. Polypectomy in premenopausal women with abnormal uterine bleeding: effectiveness of hysteroscopic removal.
Henriquez DD; van Dongen H; Wolterbeek R; Jansen FW
J Minim Invasive Gynecol; 2007; 14(1):59-63. PubMed ID: 17218231
[TBL] [Abstract][Full Text] [Related]
37. Levo-norgestrel-nova-T and precancerous lesions of the endometrium.
Scarselli G; Tantini C; Colafranceschi M; Taddei GL; Bargelli G; Venturini N; Branconi F
Eur J Gynaecol Oncol; 1988; 9(4):284-6. PubMed ID: 3391204
[TBL] [Abstract][Full Text] [Related]
38. Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study.
Tamaoka Y; Orikasa H; Sumi Y; Sakakura K; Kamei K; Nagatani M; Ezawa S
Gynecol Obstet Invest; 2004; 58(1):42-8. PubMed ID: 15087596
[TBL] [Abstract][Full Text] [Related]
39. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices.
Silverberg SG; Haukkamaa M; Arko H; Nilsson CG; Luukkainen T
Int J Gynecol Pathol; 1986; 5(3):235-41. PubMed ID: 3093395
[TBL] [Abstract][Full Text] [Related]
40. Endometrial squamous metaplasia. An unusual response to progestin therapy of hyperplasia.
Miranda MC; Mazur MT
Arch Pathol Lab Med; 1995 May; 119(5):458-60. PubMed ID: 7748076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
